The combined use of atezolizumab, a PD‐L1 inhibitor, and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, was recently approved in 2020 as the first‐line treatment for unresectable hepatocellular carcinoma (HCC) in more than 70 countries following clinically significant data from the IMbrave150 trial.7, 8. This evidence concerns the gene CD274 and hepatocellular carcinoma.